A Study of RGLS4326 in Patients With Autosomal Dominant Polycystic Kidney Disease

  • STATUS
    Recruiting
  • End date
    Dec 1, 2021
  • participants needed
    27
  • sponsor
    Regulus Therapeutics Inc.
Updated on 1 March 2021

Summary

Primary Objective

To assess the dose response relationship between RGLS4326 and ADPKD biomarkers

Secondary Objectives

  • To characterize the pharmacokinetic (PK) properties of RGLS4326 in plasma and urine
  • To assess the safety and tolerability of RGLS4326

Description

This is a Phase 1b, open-label, adaptive design dose-ranging study to evaluate ADPKD biomarkers, PK, safety, tolerability, and pharmacodynamics (PD) of RGLS4326 administered via SC injection to patients with ADPKD. The goal is to assess the dose response relationship between RGLS4326 and ADPKD biomarkers. The study will consist of three sequential cohorts with approximately 18 to 27 subjects total.

Details
Condition Polycystic Kidney, Autosomal Dominant
Treatment RGLS4326
Clinical Study IdentifierNCT04536688
SponsorRegulus Therapeutics Inc.
Last Modified on1 March 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Is your age between 18 yrs and 70 yrs?
Gender: Male or Female
Do you have Polycystic Kidney, Autosomal Dominant?
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Do you have any of these conditions: Do you have Polycystic Kidney, Autosomal Dominant??
Male or female ADPKD patients 18 to 70 years old
Class 1C, 1D, or 1E Mayo Imaging Classification of ADPKD (based upon prior MRI or CT Scan or MRI obtained during screening)
Estimated GFR at Screening between 30 to 90 mL/min/1.73 m^2 calculated by the investigator using the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI)
Body mass index (BMI) between 18 and 35 kg/m^2
If the patient has hypertension, the antihypertensive regimen must be stable for at least 28 days prior to randomization and the blood pressure adequately controlled prior to randomization
Female patients of childbearing potential must not be lactating and must have no plans to become pregnant during the course of the study through 28 days after the last dose of study drug. Female patients of childbearing potential who are heterosexual must agree to use one of the following methods of contraception considered to be highly effective (i.e., results in <1% failure rate when used consistently and correctly) from screening through 28 days after the last dose of study drug
Intrauterine device (IUD) or intrauterine system (IUS) in place for at least 3 months prior to first dose
Partner has had a vasectomy. Vasectomy in the partner is only considered to be highly effective provided the partner is the sole sexual partner of the female patient of childbearing potential and the vasectomized partner has had a medical assessment of the surgical success
Stable hormonal contraception associated with inhibition of ovulation (with approved oral, transdermal, or depot regimen) for at least 3 months prior to first dose
Bilateral tubal occlusion
Female patient of non-childbearing potential must have undergone one of the following sterilization procedures at least 6 months prior to the first dose of study drug
Hysterectomy
Bilateral oophorectomy
Bilateral tubal occlusion
Bilateral salpingectomy or be postmenopausal with no periods for at least 1 year prior to the first dose of study drug
Male patients must agree to use a condom during heterosexual intercourse and to not have unprotected sexual intercourse with a female who is pregnant or breastfeeding from screening through 28 days after the last dose of study drug; and must agree to refrain from sperm donation for at least 90 days after the last dose of study drug
Screening hematology and clinical chemistries must meet the following criteria
Platelets >150 x 10^9/L
Total white blood cell (WBC) count >3.0 x 10^9/L and absolute neutrophil count >1.5 x 10^9/L
Hemoglobin >12 g/dL for females and >13.5 g/dL for males
Total and direct bilirubin <1.5x upper limit of normal (ULN), unless elevated bilirubin is associated with a known benign condition (e.g., Gilbert's syndrome)
Alanine aminotransferase (ALT) <1.5x ULN
Aspartate aminotransferase (AST) <1.5x ULN
Alkaline phosphatase (ALP) <1.5x ULN
Gamma-glutamyl transferase (GGT) <2x ULN Note: At the discretion of the Investigator, screening laboratory testing may be repeated once to confirm out of range (exclusionary) results
Able to understand all study procedures in the informed consent form (ICF) and willing to comply with all aspects of the protocol

Exclusion Criteria

Administration of tolvaptan in the 28 days before randomization
Participation in another investigational interventional study within 28 days or 5 half-lives, whichever is longer, before randomization (e.g., bardoxolone, lixivaptan, tesevatinib, venglustat)
A history of drug and/or alcohol abuse within the past year
Active infection of the urinary tract (e.g., kidney, bladder, etc.)
Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)
Only one kidney or kidney transplant recipient
Patient has concurrent medical condition (e.g., significant infection, other kidney disease, neurologic condition such as seizures, etc.) or social situation that may either present a safety risk or noncompliance with the study procedures
History of active malignancy within 5 years of randomization, except adequately treated basal cell or squamous cell carcinoma of the skin
History of a clinically significant reaction to an oligonucleotide compound
Significant blood loss or blood donation within the 28 days prior to randomization or plasma donation within 7 days prior to randomization
A tattoo or scarring on the abdomen or any other condition large enough to interfere with the ability to assess injection site reactions
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note